Marex Group plc MRX 深 滬
已收盤 12-19 16:00:00 美东时间
39.19
+0.180
+0.46%
華盛通- 最 高39.42
- 今 開38.97
- 成交量 57.61万股
- 最 低 38.84
- 昨 收 39.01
- 總市值 28.10亿
- 52周最高 48.89
- 市盈率 靜 14.41
- 換手率 0.80%
- 52周最低 27.76
- 委 比 -0.86%
- 總股本 7169.99万
- 歷史最高 48.89
- 量 比 0.90
- 振 幅 1.49%
- 歷史最低 17.26
- 每 手 1
- 風險率 4.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Marex Launches An Online Marketplace To Connect Clients Seeking To Transfer Clean Energy Tax Credits
https://www.marex.com/news/2025/12/marex-launches-online-marketplace-transferable-clean-energy-tax-credits/
12-17 22:45
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
Barclays Maintains Overweight on Marex Group, Raises Price Target to $50
Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:MRX) with a Overweight and raises the price target from $43 to $50.
12-13 04:22
Marex Group plc completes acquisition of Winterflood and announces agreement to sell Winterflood’s custody business
Marex Group plc has acquired Winterflood Securities, enhancing its UK cash equities business, while planning to sell Winterflood Business Services (WBS) to Epiris Fund III. Marex will retain Winterflood's market making activities and brand, with WBS transferred to Epiris upon regulatory approval. The retained Winterflood business expects $75m annual revenue and a 20% profit margin. Ian Lowitt, Marex's CEO, highlighted the sale of WBS offsetting a...
12-01 12:00
Marex Group Launches Structured Products Business In US To Serve Demand From Rias, Broker-Dealers, And Private Banks Seeking Greater Issuer And Credit Diversification
Marex Group plc (("Marex", NASDAQ:MRX), the diversified global financial services platform, has launched its structured products business in the United States to serve demand from registered investment advisors (RIAs),
11-19 20:37
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Barclays Maintains Overweight on Marex Group, Raises Price Target to $43
Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:MRX) with a Overweight and raises the price target from $40 to $43.
11-07 23:36
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Marex Group to acquire Valcourt
Marex Group (NASDAQ:MRX) has agreed to acquire Valcourt SA, a fixed-income market maker based in Geneva, Switzerland. The deal is subject to regulatory approval and is expected to close in the first h...
10-22 19:14
